Preclinical Therapy of Disseminated HER-2 Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus

English version České info

Oncolytic viruses aim to specifically kill tumor cells. A major challenge is the effective targeting of disseminated tumors in vivo. We retargeted herpes simplex virus (HSV) tropism to HER-2 oncoprotein p185, overexpressed in ovary and breast cancers. The HER-2-retargeted R-LM249 exclusively infects and kills tumor cells expressing high levels of human HER-2. Here, we assessed the efficacy of systemically i.p. delivered R-LM249 against disseminated tumors in mouse models that recapitulate tumor spread to the peritoneum in women. The human ovarian carcinoma SK-OV-3 cells implanted intraperitoneally (i.p.) in immunodeficient Rag2^−/−;Il2rg^−/− mice gave rise to a progressive peritoneal carcinomatosis which mimics the fatal condition in advanced human patients. I.p. administration of R-LM249 strongly inhibited carcinomatosis, resulting in 60% of mice free from peritoneal diffusion, and 95% reduction in the total weight of neoplastic nodules. Intraperitoneal metastases are a common outcome in breast cancer: i.p. administration of R-LM249 strongly inhibited the growth of ovarian metastases of HER-2+ MDA-MB-453 breast cells. Brain metastases were also reduced. Cumulatively, upon i.p. administration the HER-2-redirected oncolytic HSV effectively reduced the growth of ovarian and breast carcinoma disseminated to the peritoneal cavity.

Vyšlo v časopise: Preclinical Therapy of Disseminated HER-2 Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus. PLoS Pathog 9(1): e32767. doi:10.1371/journal.ppat.1003155
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1003155

Souhrn

Zdroje

1. CattaneoR, MiestT, ShashkovaEV, BarryMA (2008) Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 6: 529–540.

2. Campadelli-FiumeG, De GiovanniC, GattaV, NanniP, LolliniPL, et al. (2011) Rethinking herpes simplex virus: the way to oncolytic agents. Rev Med Virol 21: 213–226.

3. RussellSJ, PengKW, BellJC (2012) Oncolytic virotherapy. Nat Biotechnol 30: 658–670.

4. MenottiL, CerretaniA, Campadelli-FiumeG (2006) A herpes simplex virus recombinant that exhibits a single-chain antibody to HER2/neu enters cells through the mammary tumor receptor, independently of the gD receptors. J Virol 80: 5531–5539.

5. MenottiL, CerretaniA, HengelH, Campadelli-FiumeG (2008) Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2. J Virol 82: 10153–10161.

6. MenottiL, NicolettiG, GattaV, CrociS, LanduzziL, et al. (2009) Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. Proc Natl Acad Sci U S A 106: 9039–9044.

7. GambiniE, ReisoliE, AppolloniI, GattaV, Campadelli-FiumeG, et al. (2012) Replication-competent Herpes Simplex Virus Retargeted to HER2 as Therapy for High-grade Glioma. Mol Ther 20: 994–1001.

8. LolliniPL, MenottiL, DeGC, Campadelli-FiumeG, NanniP (2009) Oncolytic herpes virus retargeted to HER-2. Cell Cycle 8: 2859–2860.

9. ReisoliE, GambiniE, AppolloniI, GattaV, BarilariM, et al. (2012) Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice. Cancer Gene Ther 19: 788–795.

10. Campadelli-FiumeG, AmasioM, AvitabileE, CerretaniA, ForghieriC, et al. (2007) The multipartite system that mediates entry of herpes simplex virus into the cell. Rev Med Virol 17: 313–326.

11. ChouJ, ChenJJ, GrossM, RoizmanB (1995) Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5- mutants of herpes simplex virus 1. Proc Natl Acad Sci U S A 92: 10516–10520.

12. AndreanskyS, SoroceanuL, FlotteER, ChouJ, MarkertJM, et al. (1997) Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res 57: 1502–1509.

13. Odunsi K, Pejovic T, Anderson ML (2008) Gynecologic cancers. In: DeVita DV, Lawrence TS, Rosenberg SA, editors. Principles & Practice of Oncology. Philadelphia: Lippincott. pp. 1487–1592.

14. WeigeltB, PeterseJL, van 't VeerLJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5: 591–602.

15. NarayanM, WilkenJA, HarrisLN, BaronAT, KimblerKD, et al. (2009) Trastuzumab-induced HER reprogramming in “resistant” breast carcinoma cells. Cancer Res 69: 2191–2194.

16. ShawTJ, SentermanMK, DawsonK, CraneCA, VanderhydenBC (2004) Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther 10: 1032–1042.

17. NanniP, NicolettiG, LanduzziL, CrociS, MurgoA, et al. (2010) High metastatic efficiency of human sarcoma cells in Rag2/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy. Eur J Cancer 46: 659–668.

18. NanniP, NicolettiG, PalladiniA, CrociS, MurgoA, et al. (2012) Multiorgan metastasis of human HER-2(+) breast cancer in Rag2(−)/(−);Il2rg(−)/(−) mice and treatment with PI3K inhibitor. PLoS One 7: e39626.

19. GutierrezC, SchiffR (2011) HER2: biology, detection, and clinical implications. Arch Pathol Lab Med 135: 55–62.

20. BaselgaJ, BradburyI, EidtmannH, Di CosimoS, de AzambujaE, et al. (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379: 633–640.

21. BaselgaJ, CortesJ, KimSB, ImSA, HeggR, et al. (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366: 109–119.

22. GanczD, FishelsonZ (2009) Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development. Mol Immunol 46: 2794–2800.

23. TagliabueE, CampiglioM, PupaSM, MenardS, BalsariA (2012) Activity and resistance of trastuzumab according to different clinical settings. Cancer Treat Rev 38: 212–217.

24. FuX, ZhangX (2002) Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. Cancer Res 62: 2306–2312.

25. VeerapongJ, BickenbachKA, ShaoMY, SmithKD, PosnerMC, et al. (2007) Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity. Cancer Res 67: 8301–8306.

26. SmithKD, MezhirJJ, BickenbachK, VeerapongJ, CharronJ, et al. (2006) Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1. J Virol 80: 1110–1120.

27. VargheseS, RabkinSD, NielsenGP, MacGarveyU, LiuR, et al. (2007) Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses. Cancer Res 67: 9371–9379.

28. KuluY, DorfmanJD, KuruppuD, FuchsBC, GoodwinJM, et al. (2009) Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice. Cancer Gene Ther 16: 291–297.

29. WangJ, HuP, ZengM, RabkinSD, LiuR (2012) Oncolytic herpes simplex virus treatment of metastatic breast cancer. Int J Oncol 40: 757–763.

30. FuX, TaoL, ZhangX (2007) An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer. Cancer Gene Ther 14: 480–487.

31. KemenyN, BrownK, CoveyA, KimT, BhargavaA, et al. (2006) Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther 17: 1214–1224.

32. FongY, KimT, BhargavaA, SchwartzL, BrownK, et al. (2009) A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. Mol Ther 17: 389–394.

33. GeevargheseSK, ChenA, GellerDA, de HaanHA, IagaruA, et al. (2009) Phase II efficacy results using an oncolytic herpes simplex virus (NV1020) in patients with colorectal cancer metastatic to liver (mCRC). J Clin Oncol 27: 15s [Abstract 4089].

34. BergmanI, GriffinJA, GaoY, Whitaker-DowlingP (2007) Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2/neu. Int J Cancer 121: 425–430.

35. KuruppuD, DorfmanJD, TanabeKK (2007) HSV-1 viral oncolysis and molecular imaging with PET. Curr Cancer Drug Targets 7: 175–180.

36. SchellingerhoutD, BogdanovAJr, MarecosE, SpearM, BreakefieldX, et al. (1998) Mapping the in vivo distribution of herpes simplex virions. Hum Gene Ther 9: 1543–1549.

37. BeckerM, NitscheA, NeumannC, AumannJ, JunghahnI, et al. (2002) Sensitive PCR method for the detection and real-time quantification of human cells in xenotransplantation systems. Br J Cancer 87: 1328–1335.